PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 85 filers reported holding PHATHOM PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,113,738 | -68.9% | 107,400 | -57.0% | 0.00% | – |
| Q2 2023 | $3,577,251 | +48.2% | 249,808 | -26.1% | 0.00% | – |
| Q1 2023 | $2,414,148 | +709.9% | 338,116 | +1172.7% | 0.00% | – |
| Q4 2022 | $298,082 | -73.1% | 26,567 | -73.4% | 0.00% | – |
| Q3 2022 | $1,108,000 | +73.9% | 99,999 | +32.4% | 0.00% | – |
| Q2 2022 | $637,000 | +34.1% | 75,500 | +116.3% | 0.00% | – |
| Q1 2022 | $475,000 | +40.1% | 34,900 | +249.0% | 0.00% | – |
| Q2 2021 | $339,000 | -66.0% | 10,000 | -62.3% | 0.00% | – |
| Q1 2021 | $996,000 | -69.9% | 26,505 | -73.4% | 0.00% | – |
| Q4 2020 | $3,306,000 | – | 99,518 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 3,760,869 | $39,000,212 | 12.45% |
| Frazier Life Sciences Management, L.P. | 10,109,279 | $104,833,223 | 6.96% |
| Decheng Capital Management III (Cayman), LLC | 850,000 | $8,814,500 | 2.94% |
| Carlyle Group Inc. | 3,496,808 | $36,191,963 | 1.57% |
| Ghost Tree Capital, LLC | 395,000 | $4,096,150 | 1.35% |
| Newtyn Management, LLC | 500,000 | $5,185,000 | 1.28% |
| Altium Capital Management LP | 220,000 | $2,281,400 | 1.19% |
| StepStone Group LP | 422,085 | $4,377,021 | 0.98% |
| MPM BioImpact LLC | 347,332 | $3,601,833 | 0.96% |
| NEA Management Company, LLC | 1,276,595 | $12,238,290 | 0.94% |